Transcutaneous Afferent Patterned Stimulation (TAPS) for Reduction of Parkinson's Disease (PD) Related Action Tremor

Parkinson Disease Clinical Trial

Official title:

A Study of Safety and Efficacy of Transcutaneous Afferent Patterned Stimulation (TAPS) for Reduction of Action Tremor in Parkinson's Disease (PD)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05012579
• Other study ID #: PD-02
• Status: Completed
• Phase: N/A
• Start date: November 11, 2020
• Est. completion date: March 12, 2021

Study information

• Verified date: January 2024
• Source: Cala Health, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Demonstrate safety and efficacy of TAPS delivered by a Cala device as a treatment for action tremor in subjects with Parkinson's disease hand tremor

Description:

40 patients with PD with at least mild postural tremor were enrolled in a four-week, prospective, single-arm, open-label study of twice daily TAPS therapy. Due to the COVID-19 pandemic, TAPS devices were shipped to patients to run the study remotely. Unsupervised motion assessments were captured at home, and at the beginning and end of the four weeks by telemedicine.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: March 12, 2021
• Est. primary completion date: March 12, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 22 Years and older

Eligibility

Inclusion Criteria:

• Must be =22 years of age

• Competent and willing to provide written, informed consent to participate in the study

• Clinically significant postural tremor as defined by:

• Dominant hand/arm exhibiting postural tremor = 2 (while in the off state) as assessed by the MDS-UPDRS postural tremor score

• Stable dose of Parkinson's disease medications, if applicable, for 30 days prior to study entry

• Willing to comply with study protocol requirements including:

• Having the ability to do telemedicine or video calls for study visits

• remaining on a stable dosage of Parkinson's medications, if applicable, during the duration of the study

• no significant caffeine consumption within 8 hours of study visits

Exclusion Criteria:

• Implanted electrical medical device, such as a pacemaker, defibrillator, or deep brain stimulator

• Suspected or diagnosed epilepsy or other seizure disorder

• Swollen, infected, inflamed areas, or skin eruptions, open wounds, or cancerous lesions of skin at stimulation site

• Peripheral neuropathy affecting the tested upper extremity

• Presence of any other neurodegenerative disease or dementia. These may include:

multisystem atrophy, progressive supranuclear palsy, dementia with Lewy bodies, and Alzheimer's disease.

• Botulinum toxin injection for hand tremor within 6 months prior to study enrollment

• Are participating or have participated in another interventional clinical trial in the last 30 days which may confound the results of this study, unless approved by the Sponsor

• Significant caffeine consumption within 8 hours of study enrollment, which may confound the results of the study, where significant caffeine is considered more than 95 mg (equivalent to a cup of coffee).

• Subjects unable to communicate with the investigator and staff

• Any health condition that in the investigator's opinion should preclude participation in this study

• Pregnancy or anticipated pregnancy during the course of the study

Related Conditions & MeSH terms

• Parkinson Disease
• Tremor

Intervention

Device:
• Cala Device
transcutaneous afferent patterned stimulation (TAPS)

Locations

Country	Name	City	State
United States	Cala Clinic	Burlingame	California

Sponsors (1)

Lead Sponsor	Collaborator
Cala Health, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Tremor Power	Pre-specified effectiveness endpoints included improvements in (1) objective postural tremor power (primary outcome; assessed using an accelerometer on the device under standard of care medication state at home).	4 weeks
Secondary	Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS)	Improvement of clinician-ratings of Movement Disorder Society Unified PD Rating Scale (MDS-UPDRS) Part III [Goetz, C.G. et al. Wiley Intersci. 2008] (co-secondary; in medication-off state). Clinician rated patients' tremor pre and post therapy on a scale of 0-4. 0=Normal (no tremor), 4=Severe.	4 weeks
Secondary	Bain and Findley Activities of Daily Living (BF-ADL)	Improvement of patient-ratings of the Bain and Findley Activities of Daily Living (BF-ADL) [Bain PG, et al. Journal of Neurol, Neuros & Psych 1993] (co-secondary; in medication-off state). Patients' rated ability to perform specific activities pre and post therapy on a scale from 1-4. 1=Able to do the activity without difficulty, 4=Cannot do the activity by yourself.	4 weeks
Secondary	Percentage of Patients With Clinician and Patient Global Impressions of Improvement Rated < 4 (CGI-I, PGI-I)	Clinician and Patient global impressions of improvement (CGI-I, PGI-I; exploratory) post therapy. This is a rated scale from 1-7, with 1=Very Much Improved to 7=Very Much Worse. Percentage of patients with ratings < 4 (including very much improved, much improved and improved) were computed respectively for CGI-I and PGI-I.	4 weeks